LYRA
Lyra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.19
+0.00%Year over year
Reported trailing growth
- Revenue
- -74.1%
- EBITDA
- +48.5%
- EBIT
- +67.8%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -33.7%
- EBITDA
- +48.5%
- EBIT
- +67.8%
- Net income
- +69.0%
- EPS
- —
- Free cash flow
- +60.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025